Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (261-270 of 303) with videos related to

Pageof 31
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Journal of Neurotrauma|September 23, 2017
Military Blast Injury and Chronic Neurodegeneration: Research Presentations from the 2015 International State-of-the-Science MeetingDenes Agoston, Peethambaran Arun, Patrick Bellgowan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Nature Reviews. Clinical Oncology|September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemiaAntonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Pageof 31

Showing results (261-270 of 303) with videos related to

Sort By:
Pageof 31
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Journal of Neurotrauma|September 23, 2017
Military Blast Injury and Chronic Neurodegeneration: Research Presentations from the 2015 International State-of-the-Science MeetingDenes Agoston, Peethambaran Arun, Patrick Bellgowan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Nature Reviews. Clinical Oncology|September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemiaAntonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Pageof 31